C. elegans expressing human β2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype
- PMID: 23284985
- PMCID: PMC3528749
- DOI: 10.1371/journal.pone.0052314
C. elegans expressing human β2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype
Abstract
Availability of living organisms to mimic key step of amyloidogenesis of human protein has become an indispensable tool for our translation approach aiming at filling the deep gap existing between the biophysical and biochemical data obtained in vitro and the pathological features observed in patients. Human β(2)-microglobulin (β(2)-m) causes systemic amyloidosis in haemodialysed patients. The structure, misfolding propensity, kinetics of fibrillogenesis and cytotoxicity of this protein, in vitro, have been studied more extensively than for any other globular protein. However, no suitable animal model for β(2)-m amyloidosis has been so far reported. We have now established and characterized three new transgenic C. elegans strains expressing wild type human β(2)-m and two highly amyloidogenic isoforms: P32G variant and the truncated form ΔN6 lacking of the 6 N-terminal residues. The expression of human β(2)-m affects the larval growth of C. elegans and the severity of the damage correlates with the intrinsic propensity to self-aggregate that has been reported in previous in vitro studies. We have no evidence of the formation of amyloid deposits in the body-wall muscles of worms. However, we discovered a strict correlation between the pathological phenotype and the presence of oligomeric species recognized by the A11 antibody. The strains expressing human β(2)-m exhibit a locomotory defect quantified with the body bends assay. Here we show that tetracyclines can correct this abnormality confirming that these compounds are able to protect a living organism from the proteotoxicity of human β(2)-m.
Conflict of interest statement
Figures





Similar articles
-
C. elegans expressing D76N β2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis.Sci Rep. 2019 Dec 27;9(1):19960. doi: 10.1038/s41598-019-56498-5. Sci Rep. 2019. PMID: 31882874 Free PMC article.
-
Global Proteotoxicity Caused by Human β2 Microglobulin Variants Impairs the Unfolded Protein Response in C. elegans.Int J Mol Sci. 2021 Oct 4;22(19):10752. doi: 10.3390/ijms221910752. Int J Mol Sci. 2021. PMID: 34639093 Free PMC article.
-
Human wild-type and D76N β2-microglobulin variants are significant proteotoxic and metabolic stressors for transgenic C. elegans.FASEB Bioadv. 2023 Oct 25;5(11):484-505. doi: 10.1096/fba.2023-00073. eCollection 2023 Nov. FASEB Bioadv. 2023. PMID: 37936921 Free PMC article.
-
Systemic amyloidosis: lessons from β2-microglobulin.J Biol Chem. 2015 Apr 17;290(16):9951-8. doi: 10.1074/jbc.R115.639799. Epub 2015 Mar 6. J Biol Chem. 2015. PMID: 25750126 Free PMC article. Review.
-
Limited proteolysis in the investigation of beta2-microglobulin amyloidogenic and fibrillar states.Biochim Biophys Acta. 2005 Nov 10;1753(1):44-50. doi: 10.1016/j.bbapap.2005.09.004. Epub 2005 Sep 23. Biochim Biophys Acta. 2005. PMID: 16213198 Review.
Cited by
-
HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders.Sci Rep. 2017 Sep 4;7(1):10313. doi: 10.1038/s41598-017-10875-0. Sci Rep. 2017. PMID: 28871125 Free PMC article.
-
In vitro aggregating β-lactamase-polyQ chimeras do not induce toxic effects in an in vivo Caenorhabditis elegans model.J Negat Results Biomed. 2017 Aug 22;16(1):14. doi: 10.1186/s12952-017-0080-5. J Negat Results Biomed. 2017. PMID: 28830560 Free PMC article.
-
Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegans.Dis Model Mech. 2025 Jul 1;18(7):dmm052230. doi: 10.1242/dmm.052230. Epub 2025 Jul 25. Dis Model Mech. 2025. PMID: 40709584 Free PMC article.
-
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans.Worm. 2014 Oct 30;3(3):e965590. doi: 10.4161/21624046.2014.965590. eCollection 2014 Jul-Sep. Worm. 2014. PMID: 26430549 Free PMC article.
-
C. elegans expressing D76N β2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis.Sci Rep. 2019 Dec 27;9(1):19960. doi: 10.1038/s41598-019-56498-5. Sci Rep. 2019. PMID: 31882874 Free PMC article.
References
-
- Link CD (2005) Invertebrate models of Alzheimer's disease. Genes Brain Behav 4: 147–156. - PubMed
-
- Lakso M, Vartiainen S, Moilanen AM, Sirviö J, Thomas JH, et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86: 165–172. - PubMed
-
- Luo Y, Wu Y, Brown M, Link CD (2009) Caenorhabditis elegans Model for Initial Screening and Mechanistic Evaluation of Potential New Drugs for Aging and Alzheimer's Disease. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press; Chapter 16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous